Abstract: Relatively low levels of polysaccharides in combination with small, deformable, water-insoluble particles of a size in the range 0.05-5 microns are capable of giving benefits in a wash liquor in terms of reduced fabric abrasion.

Abstract: A pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief along with decongestant relief, over extended time periods.

Abstract: The invention relates to coating and encapsulation composition useful for protecting core material from oxidative and/or hydrolytic damage. The coating composition comprises a lipid polymer and a lipid-based anti-oxidant, wherein the anti-oxidant is soluble in the lipid polymer.

Abstract: The present invention relates to a controlled release system that can be incorporated in cosmetic, personal care, and household products to effectively encapsulate wide range of active ingredients and sensory markers and release them in response to moisture or over an extended period of time. The controlled release system of the present invention consists of oil absorbing polymer nanospheres coated with water sensitive surface active polymers.

Abstract: A composition comprises a non-ionic surfactant and hydrophobic particles of metal oxide having the mean length of the primary particles in the range from 50 to 90 nm, the mean width of the primary particles in the range from 5 to 20 nm, and the median volume particle diameter of the secondary particles is less than 45 nm. The composition is particularly suitable for use in aqueous media, and can be used in a sunscreen product that exhibits both effective UV protection and improved transparency.

Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.

Abstract: Pharmaceutical compositions of a particularly effective sparingly soluble glycogen phosphorylase inhibitor are disclosed, as well as methods of making such compositions and dosage forms from such compositions.

Abstract: The present invention is directed to parenterally-administrable microparticles for providing sustained-release of a therapeutic agent in the body, where the microparticles include a polymeric core containing a therapeutically effective amount of a therapeutic agent disposed therein, a first film encapsulating the core, the first film prepared from a first biodegradable polymer soluble in an appropriate solvent therefore, and a second film encapsulating the core and the first film, the second film prepared from a biodegradable polymer soluble in an appropriate solvent therefore, wherein the first film is insoluble in the solvent used to prepare the second film, and to parenterally-administrable compositions containing such microparticles dispersed in a suitable carrier therefore.

Abstract: This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. Applicants disclose a method of identifying an optimal form of aerodynamically light particles which are highly dispersible. The particles of the instant invention are made by creating hollow, spherical drug particles (i.e., progenitor particles) that collapse in the process of particle formation, leading to wrinkled, thin-walled drug particles of very low envelope density. Additionally, Applicants have found that such particles are especially optimal for inhaled aerosols when the surface area parameter (?) is greater than 2, optimally greater than 3.

Abstract: An emulsifier mixture for use in a wax-based opacifier composition is comprised of: (a) an alkyl and/or alkenyl oligoglycoside; (b) a fatty acid partial glyceride and optionally (c) at least one amphoteric surfactant, with the proviso that the ratio by weight of (a) and optionally (c) to (b) is between 6:1 and 3:1 and wherein the composition is free from anionic surfactants.

Abstract: A highly magnetically aligned metallothionein (MT) containing manganese (Mn) and cadmium (Cd) has been synthesized. The metallotionein has a formula of Mnx Cd7?x MT with x being in the range of 1 to 6. Its size and biological functions are similar as those of the native metallothionein as tested by dynamic light scattering, UV, and CD spectroscopic experimental methods. Its maximum magnetic moment per formula unit, in saturation field, is estimated to be 19.46 ?B, and persists from 277 to 330 K.

Abstract: The present inventive subject matter relates to amorphous drug beads comprising an amorphous active drug and an organic surfactant having improved solubility, absorption and wettability characteristics. The present inventive subject matter further relates to methods of preparing the amorphous drug beads, wherein molten drug beads are subject to a cooling step with or without shear.

Abstract: The invention is directed to biologically active lipophilic compositions comprising a biologically active covalently attached to, or encapsulated within, a lipid. Preferably, a biologically active agent is both covalently attached to a lipid and encapsulated within a lipid composition. Preferred lipid components include triglycerides and fatty acids. The resulting composition is preferably adapted for oral administration.

Abstract: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.

Abstract: A process for making hydrophobicized powders of micro- and/or nanocapsules involving the steps of: (a) providing an aqueous polymer solution containing at least one active ingredient and at least one hydrophilic polymer; (b) providing an oil component heated to a temperature above a gel point of the aqueous polymer solution; (c) dispersing (a) in (b) in the presence of a water-in-oil emulsifier to form a dispersion; (d) cooling the dispersion to a temperature below the gel point of the aqueous polymer solution to form micro- and/or nanocapsules containing the active ingredient encapsulated therein; (e) harvesting the micro- and/or nanocapsules from the dispersion; and (f) contacting the micro- and/or nanocapsules with an oil-absorbing auxiliary ingredient.

Abstract: The present invention relates to cosmetic formulations comprising a multi component controlled release system that imparts long lasting cooling sensation and/or provides high odor or flavor intensity (i.e., high impact fragrance or flavor burst) in response to moisture. The controlled delivery system of the present invention is substantially free-flowing powder formed of solid hydrophobic nano-spheres that are encapsulated in a moisture sensitive micro-spheres.

Abstract: A method of enhancing a culturing characteristic of fish larvae, including administering to said larvae in a nutritional diet essential fatty acids including DHA and AA in a ratio effective to enhance the culturing characteristic of such fish larvae relative to a corresponding nutritional diet lacking DHA and AA. The culturing characteristic may be at least one of stress resistance, immunoresistance, hatching rate, and growth rate. In a preferred aspect, the DHA and AA together comprise from about 10 to about 30% of total fatty acids in enrichment lipids, and the dietary ratio of DHA: AA is less than 10.

Abstract: An improved soft gelatin formulation and process methodology that increases single Coenzyme Q10 molecules presented to the absorption channels of the small intestines by providing medium chain triglycerides, Vitamin E and natural beta carotene to Coenzyme Q10 in a soft gel capsule to increase the absorption thereof.

Abstract: The present invention is directed to medical devices and pharmaceutical or agricultural compositions, and seeds, each containing a synthetic, bioabsorbable, biocompatible polymeric wax that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the polymeric wax having a melting point less than about 70° C., as determined by differential scanning calorimetry, and an effective amount of rapamycin or an analogue thereof.

Abstract: Nanoparticles are prepared from a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material. A microemulsion is formed by admixing the colloidal system with a solution of an active material, such as a medicament, dissolved in a solvent wherein the solution forms a disperse phase with the micelles of surfactant material. At least the dispersed phase is quenched to a solid state and the continuous phase and solvent are removed to produce the nanoparticles. The nanoparticles can be incorporated in an aerosol composition suitable for deep lung delivery by means of a metered dose inhaler.

Abstract: This invention refers to: multiparticulate formulations of Lithium salts for oral administration constituted by either modified release granules or mixtures of modified and conventional release granules, suitable for once-a-day administration also at high strengths of Lithium salts, and to the preparation process of said formulations.

Abstract: Particles of water insoluble biologically active compounds, particularly water-insoluble drugs, with an average size of 100 nm to about 300 nm, are prepared by dissolving the compound in a solution then spraying the solution into compressed gaz, liquid or supercritical fluid in the presence of appropriate surface modifiers.

Abstract: Microcapsules comprising an agglomeration of primary microcapsules, each individual primary microcapsule having a primary shell and the agglomeration being encapsulated by an outer shell, may be prepared by providing an aqueous mixture of a loading substance and a shell material, adjusting pH, temperature, concentration and/or mixing speed to form primary shells of shell material around the loading substance and cooling the aqueous mixture until the primary shells agglomerate and an outer shell of shell material forms around the agglomeration. Such microcapsules are useful for storing a substance and for delivering the substance to a desired environment.

Abstract: Described herein are microcapsules and emulsions prepared from low Bloom gelatin and methods of making and using thereof.

Abstract: A process for making microcapsules of an oil which are in dispersion in water comprises the steps of; (i) forming an initial dispersion of the oil in water in the presence of a surfactant, (ii) heating the initial dispersion above its phase inversion temperature, to form a bicontinuous phase composition, (iii) allowing or causing the composition to cool to below the phase inversion temperature so as to form an emulsion of oil droplets in the water, and (iv) encapsulating the oil droplets. The oil preferably has dissolved in it an oil-soluble or oil-dispersible active ingredient selected from agrochemicals, cosmetics, fragrances, sun-screens, ink-jet dyes, pigments, toners, biocides and pharmaceutical and veterinary products including drug delivery systems.

Abstract: Disclosed is a process for producing sustained-release powders that is fast, efficient, and economical. The process involves melting an animal or vegetable oil with a melting point above 110 degrees F. in specially designed mixer through either the work energy input of the mixer shaft itself, or a specially fitted plow type mixer equipped with a heating tank, cooling unit, jacket for hot water circulation, and heated lines with nozzles for atomizing the hot oil to be sprayed on. The entire manufacturing process can be completed in about 5-30 minutes, and results in small, sustained-release particles that are free flowing and solid at room temperature. The preferred oil is a hydrogenated soy oil with a melting point range of 145-160 degrees F. which is applied at about a 5% level by weight in a high shear mixer. Also included are sustained-release compositions for therapeutic agents such as drugs, botanicals, biological agents, fungicides, and fertilizers.

Abstract: The present invention provides pro-micelle compositions comprising a pharmaceutically active agent encapsulated with a membrane of esterified C12-C18 fatty acids. In the mammalian intestine, exposure to C12-C18 fatty acids results in conversion of the pro-micelle to a stable micelle that effectively delivers the pharmaceutically active agent to the systemic circulation. The present invention further provides methods of making and using such compositions.

Abstract: The present invention provides a pharmaceutical composition which is substantially free of unpleasant tastes and orally administrable which comprises: (a) an active medicament, (b) an inner coating layer comprising an oil substance having a melting point at a range of from about 50° C. to about 100° C., (c) an outer coating layer comprising at least a polymeric substance.

Abstract: The present invention provides a process for preparing hardshell gelatin capsule reducing the static electricity and enhancing the lubrication of film having good film distribution in capsule comprising the steps of: i) preparing an emulsion containing 0.4˜0.8 part by weight of diacetylated monoglycerides, 0.05˜0.1 part by weight of sodium lauryl sulfate, and 0.005˜0.01 part by weight of colloidal silicon dioxide; ii) adding the emulsion to gelatin solution containing 100 part by weight of gelatin; iii) mixing and homogenizing the resulting solution; iv) adjusting viscosity of mixture; v) allowing the obtained product to stand; and vi) forming a hardshell gelatin capsule therefrom.

Abstract: A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

Abstract: A composition and method for enhancing skin adhesion of cosmetics by using pigments and extender pigments for the cosmetics, which pigments and extender pigments are treated with at least one hydrophobidizing agent and/or hydrophobidizing/lipophobidizing agent and one or more high viscosity esters having a viscosity in excess of 30 cps. The present invention further comprises such coated pigments and extender pigments as well as cosmetics made therewith.

Abstract: A novel method of encapsulating an active substance in a biodegradable polymer, which comprises: a) dissolving said biodegradable polymer in an organic solvent therefor; b1) dispersing said active substance in the organic solution obtained in step a) to provide a dispersion with the active substance as the inner phase thereof; or alternatively b2) emulsifying said active substance, dissolved in water or other aqueous solvent therefor, in the organic solution obtained in step a) to provide an emulsion with the active substance as the inner aqueous phase thereof; and c) subjecting the dispersion obtained in step b1), or alternatively the emulsion obtained in step b2), to an encapsulation operation with an aqueous polyethylene glycol solution as a continuous phase to provide micro- or nanoparticles having the active substance encapsulated therein. Sustained release particles obtainable thereby.

Abstract: Pasture grass and legume seeds are protected with an outer coating of insoluble fatty acid salts. The coated seeds are fed to ruminants and bypass their digestive tract. When the coated seeds exit the digestive tract in the manure, they provide ranchers a no-till broadcast technique to easily reseed or improve pasture forage. Legume seeds are preferably coated twice, first with Rhizobia and then with the insoluble fatty acid salts. The Rhizobia coating will improve the legume rate of growth. Alternatively, discreet particles of Rhizobia can be coated with insoluble fatty acid salts and fed to the ruminants along with coated legume seeds.

Abstract: A synthetic particulate vector comprising a non-liquid hydrophilic nucleus which does not have an external lipid layer grafted thereon. A method for preparing a particulate vector by encapsulating an ionizable active principle, vectors obtainable through said method, and pharmaceutical, cosmetological or food compositions containing such vectors are also disclosed.

Abstract: The present invention provides a time-release dosage form for delivering an acid-labile pharmaceutical, such as omeprazole, into the upper portion of the gastrointestinal tract downstream of the stomach. The dosage form includes a drug-containing core surrounded by an inert time-release coating that delays release of the drug from the core until expiration of a certain time period after administration, generally 0.5-5.0 hours or 1-3 hours. When the gastrointestinal fluid contacts the core, the drug is released rapidly into the GI tract. The dosage form does not contain an enteric coating. The dosage form can also include one or more additional coatings exterior to the time-release coating to provide delivery of an immediately released loading dose of the acid-labile drug or another drug.

Abstract: It comprises a compound having antifungal activity as active principle, an inert core and a coating including said active principle, and is characterized in that said inert core has a particle size comprised between 50 and 600 &mgr;m, and in that said coating comprises a single layer obtained by spraying, on said inert core, a solution comprising a compound having antifungal activity, a hydrophilic polymer and a non-ionic surfactant. The method consists in carrying out a coating, comprising a single layer, of the inert cores having a size between 50 and 600 &mgr;m, by means of the spraying of a solution composed by the antifungal agent, the hydrophilic polymer and the non-ionic surfactant, at a constant coating speed throughout the whole process; and a single drying step of said coating in the same apparatus.

Abstract: The invention concerns a pharmaceutical composition with prolonged release, for oral administration of a single daily dose of 60 to 140 mg of Milnacipran, having a multi-particulate form containing a plurality of microgranules each comprising an active microsphere containing a saccharose and/or starch nucleus of a size between 200 and 2000 &mgr;m and containing 150 to 1000 &mgr;m of Milnacipran and a binding agent, each microgranule being coated with a film having a base of at least one polymer insoluble in water but permeable to physiological liquids, of a thickness between 20 and 100 &mgr;m, the said pharmaceutical composition enabling an in vitro release corresponding to the following pattern: between 10 and 55% of the dose released in 2 hours, between 40 and 75% of the dose released in 4 hours, between 70 and 90% of the dose released in 8 hours, between 80 and 100% of the dose released in 12 hours.

Abstract: The invention relates to a method for producing capsules provided with a polyelectrolyte covering, and to the capsules obtained using this method.

Abstract: A method and a process are disclosed for preparation of medical electro-powders. The electro-powder results from preparations of chemical and biological substances to form electro-powders suitable for electrostatic charging and dosing for functionality in a dry powder inhaler device. The electro-powder resulting from the method and process forms an active powder substance or a dry powder medical formulation with a fine particle fraction representing of the order 50% or more of the content having a size ranging between 0.5-5 &mgr;m and provides electrostatic properties with an absolute specific charge per mass after charging of the order 0.1×10−6 to 25×10−6 C/g and presenting a charge decay rate constant Q50>0.1 sec with a tap density of less than 0.8 g/ml and a water activity aw of less than 0.5.

Abstract: The present invention discloses sustained release particles having a mean particle size of 300 &mgr;m, or less, comprising a drug-containing core substance coated with a mixed coating of a hydrophobic organic compound-water-insoluble polymer, which prevents sticking during compression molding when producing oral sustained release tablets, a preparation method of those sustained release particles, and a preparation method of tablets using those sustained release particles.

Abstract: Novel emulsion compositions which improve the rate and/or extent of absorption of drugs are disclosed. The novel emulsion compositions of the present invention include drug-containing emulsions adsorbed onto solid particles which may be further formulated into solid dosage forms, methods of preparing such emulsion compositions and their uses thereof. The emulsion compositions and their dosage forms improve the drug-load and the bioavailability of a wide range of drugs including drugs that are known or suspected of having poor bioavailability by the utilization of several different mechanisms.

Abstract: Tocopherol derivatives are provided. In one embodiment, the tocopherol derivative includes a tocopherol moiety covalently coupled to branched hydrophilic moiety. In another embodiment, the tocopherol derivative includes a first tocopherol moiety covalently coupled to a second tocopherol moiety through a hydrophilic moiety. In other embodiments, the derivative includes three or more tocopherol moieties.

Abstract: Disclosed herein is an aqueous suspension of insecticidally active compounds comprising a solid active compound applied as a coating to an inorganic carrier and auxiliaries, water and glycerol.

Abstract: A pharmaceutical composition for oral use is disclosed. It includes, as active principle, a drug liable to undergo a strong first intestinal passage effect and a carrier which is self-micro-emulsifying on contact with an aqueous phase. The carrier includes: a therapeutically effective amount of the active principle; a lipophilic phase, which is a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with at least one fatty acid chosen from the group comprising C8-C18 fatty acids; a surfactant phase which is a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with caprylic acid (C8) and capric acid (C10); a co-surfactant phase which is an ester of a polyvalent alcohol with at least one fatty acid chosen from the group comprising caprylic esters of propylene glycol, lauric esters of propylene glycol and oleic esters of polyglycerol. A method of decreasing the effect of intestinal metabolism on a drug using the composition is also disclosed.

Abstract: The invention relates to carrier particles for use in pharmaceutical compositions for the pulmonary administration of medicaments by means of dry powder inhalers. In particular, the invention relates to a novel technological process for obtaining a carrier modified so as to improve the efficiency of redispersion of active particles and hence increase the respirable fraction. After the treatment of the invention, the surface of said modified carrier particles can also be coated with a suitable additive so as to further improve the respirable fraction.

Abstract: A process is described for preparing dry powders of one or more oxygenated carotenoids by a) dispersing one or more oxygenated carotenoids in an aqueous molecular dispersion or colloidal dispersion of a protecting colloid and b) converting the dispersion formed into a dry powder by removing the water and any solvents additionally used and drying, in the presence or absence of a coating material, which comprises using as protecting colloid in process step a) at least one partially hydrolyzed soybean protein having a degree of hydrolysis greater than 5%.

Abstract: A preparation capable of releasing a medicinal substance at a targeted site in the intestine, wherein the preparation dose not releases medicinal substance in endogastri at all, but can quickly release a medicinal substance when it reaches the desired site in the intestine after a certain period of time from discharge of the preparation from the stomach, and wherein a core material containing a medicinal substance is coated with a mixed film of a hydrophobic organic compound—an enteric polymer.

Abstract: A new soft gelatine formulation and process methodology is disclosed herein that increases single Coenzyme Q10 molecules presented to the absorption channels of the small intestines by providing medium chain triglycerides, Vitamin E, and natural beta carotene to Coenzyme Q10 in a soft gel capsule to increase the absorption thereof.

Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.

Abstract: An injectable physiologically acceptable aqueous phase fluorocarbon emulsion, which has substantially no free fluorocarbon, has an excellent stability is prepared by a process of the invention. Typically, more than about 99.8 wt. % of the fluorocarbon remains in the size range of about 0.2 to 0.4 microns even after being stored at room temperature for one year or more in sealed containers under a non-oxidizing atmosphere. The emulsion is useful in medical applications, for example, coronary angioplasty, cancer therapy, among others.